NO20076431L - Pyridazinderivater - Google Patents

Pyridazinderivater

Info

Publication number
NO20076431L
NO20076431L NO20076431A NO20076431A NO20076431L NO 20076431 L NO20076431 L NO 20076431L NO 20076431 A NO20076431 A NO 20076431A NO 20076431 A NO20076431 A NO 20076431A NO 20076431 L NO20076431 L NO 20076431L
Authority
NO
Norway
Prior art keywords
pyridazine derivative
pyridazine
derivative
rhar
esters
Prior art date
Application number
NO20076431A
Other languages
English (en)
Norwegian (no)
Inventor
Werner Neidhart
Bernd Kuhn
Alexander Mayweg
Kurt Amrein
Daniel Hunziker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20076431(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20076431L publication Critical patent/NO20076431L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20076431A 2005-07-05 2007-12-14 Pyridazinderivater NO20076431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05106098 2005-07-05
PCT/EP2006/063533 WO2007003521A2 (en) 2005-07-05 2006-06-26 Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors

Publications (1)

Publication Number Publication Date
NO20076431L true NO20076431L (no) 2008-04-01

Family

ID=36781523

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076431A NO20076431L (no) 2005-07-05 2007-12-14 Pyridazinderivater

Country Status (32)

Country Link
US (1) US7678795B2 (sr)
EP (1) EP1904455B1 (sr)
JP (1) JP4787321B2 (sr)
KR (1) KR100979582B1 (sr)
CN (1) CN101528713B (sr)
AR (1) AR054814A1 (sr)
AT (1) ATE520670T1 (sr)
AU (1) AU2006265201C1 (sr)
BR (1) BRPI0613565A2 (sr)
CA (1) CA2612740C (sr)
CL (1) CL2009001936A1 (sr)
CR (1) CR9587A (sr)
CY (1) CY1112401T1 (sr)
DK (1) DK1904455T3 (sr)
EC (1) ECSP088082A (sr)
ES (1) ES2370039T3 (sr)
HR (1) HRP20110808T1 (sr)
IL (1) IL188182A (sr)
MA (1) MA29909B1 (sr)
MX (1) MX2007016352A (sr)
MY (1) MY144209A (sr)
NO (1) NO20076431L (sr)
NZ (1) NZ564260A (sr)
PL (1) PL1904455T3 (sr)
PT (1) PT1904455E (sr)
RS (1) RS51994B (sr)
RU (1) RU2401832C2 (sr)
SI (1) SI1904455T1 (sr)
TW (1) TWI323258B (sr)
UA (1) UA94052C2 (sr)
WO (1) WO2007003521A2 (sr)
ZA (1) ZA200710972B (sr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
TW201010975A (en) 2008-08-29 2010-03-16 Kowa Co 1-adamantylazetidin-2-one derivatives and drugs containing same
WO2010050191A1 (ja) 2008-10-29 2010-05-06 興和株式会社 １，２－ジアゼチジン－３－オン誘導体及びこれを含有する医薬
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012154967A1 (en) * 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2929194A1 (en) * 2013-11-05 2015-05-14 F. Hoffmann-La Roche Ag 5,6,7,8-tetrahydro-5,8-methanocinnoline derivatives as rorc modulators for the treatment of autoimmune diseases
CN107531644B (zh) * 2015-05-04 2021-07-27 豪夫迈·罗氏有限公司 作为RORc调节剂的哒嗪衍生物
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
CN110225907A (zh) * 2016-11-01 2019-09-10 豪夫迈·罗氏有限公司 作为RORc调节剂的哒嗪衍生物
WO2020033919A1 (en) 2018-08-10 2020-02-13 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
KR102780960B1 (ko) * 2021-10-19 2025-03-12 조선대학교산학협력단 대사성 질환의 예방 또는 치료용 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356487A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd. 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
CN1628109A (zh) * 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
ES2338656T3 (es) 2003-04-11 2010-05-11 High Point Pharmaceuticals, Llc Uso farmaceutico de 1,2,4-triazoles fusionados.

Also Published As

Publication number Publication date
ZA200710972B (en) 2008-10-29
CA2612740A1 (en) 2007-01-11
WO2007003521A2 (en) 2007-01-11
HRP20110808T1 (hr) 2011-12-31
IL188182A (en) 2011-10-31
ATE520670T1 (de) 2011-09-15
MY144209A (en) 2011-08-15
CN101528713A (zh) 2009-09-09
AR054814A1 (es) 2007-07-18
BRPI0613565A2 (pt) 2011-01-18
CL2009001936A1 (es) 2010-02-19
SI1904455T1 (sl) 2011-11-30
TWI323258B (en) 2010-04-11
NZ564260A (en) 2010-12-24
CN101528713B (zh) 2013-05-22
US7678795B2 (en) 2010-03-16
RU2008103483A (ru) 2009-08-10
UA94052C2 (uk) 2011-04-11
PT1904455E (pt) 2011-10-04
HK1134087A1 (en) 2010-04-16
CY1112401T1 (el) 2015-12-09
EP1904455A2 (en) 2008-04-02
WO2007003521A3 (en) 2009-02-05
KR20080019272A (ko) 2008-03-03
MA29909B1 (fr) 2008-11-03
PL1904455T3 (pl) 2012-01-31
IL188182A0 (en) 2008-03-20
RS51994B (sr) 2012-04-30
RU2401832C2 (ru) 2010-10-20
AU2006265201B2 (en) 2010-07-15
CR9587A (es) 2008-01-25
EP1904455B1 (en) 2011-08-17
ECSP088082A (es) 2008-02-20
ES2370039T3 (es) 2011-12-12
AU2006265201A1 (en) 2007-01-11
KR100979582B1 (ko) 2010-09-01
US20070010519A1 (en) 2007-01-11
JP4787321B2 (ja) 2011-10-05
CA2612740C (en) 2011-07-26
DK1904455T3 (da) 2011-09-12
AU2006265201C1 (en) 2010-12-09
TW200738241A (en) 2007-10-16
MX2007016352A (es) 2008-03-05
JP2009500370A (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
NO20076431L (no) Pyridazinderivater
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
MX2010005824A (es) Derivados de aminotiazol.
NO20091548L (no) Imidazolon- og imidazolidinonderivater som 11B-HSD1 inhibitorer for diabetes
NO20080554L (no) Pyrazolonderivater
MXPA05008172A (es) Derivados de malonamida como inhibidores gamma-secretasa.
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
MX2009006756A (es) Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv.
WO2005051906A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2009115517A3 (en) Pyridines and pyrazines as inhibitors of pi3k
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
NO20070445L (no) Pyrimidinderivater.
NO20082159L (no) Triazolopyridinderivater som inhibitorer av lipaser og fosfolipaser
MX2012000414A (es) Derivados piridin-4-ilo.
IN2012DN03337A (sr)
NO20081942L (no) Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
MX2010005714A (es) Compuestos de piridina.
GB0314967D0 (en) Piperazine derivatives
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
WO2007046867A3 (en) Piperidine derivatives and their uses as therapeutic agents
WO2009016081A3 (en) Benzoind0l-2-one derivatives for use in therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application